FINWIRES · TerminalLIVE
FINWIRES

HKG:2617

7 stories mentioning HKG:2617Updated 19d ago

Every FINWIRES story that references HKG:2617, newest first.

Asia

TransThera Sciences Completes HK$157 Million Share Offering

TransThera Sciences (Nanjing) (HKG:2617) said it completed a HK$156.6 million share offering, according to a Wednesday filing with the Hong Kong bourse.The drugmaker's shares fell over 5% in late morning trade Thursday.The company sold 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product, tinengotinib.The shares represent 1.23% of the company's existing H shares and 0.94% of its enlarged share capital.

HKG:2617
Asia

TransThera Sciences Gets China Approval for Cancer Study; to Partner with Shanghai Allist Pharma on Phase 2 Trial

TransThera Sciences (Nanjing) (HKG:2617) said Chinese regulators approved its phase 2 clinical trial of tinengotinib to treat prostate cancer, according to a Tuesday filing with the Hong Kong bourse.The company's shares fell over 3% in afternoon trade Wednesday.The firm will evaluate a combination of tinengotinib and novel hormone therapy in an open-label study in subjects with metastatic castration-resistant prostate cancer.In a separate announcement, the firm said it is partnering with Shanghai Allist Pharmaceuticals on another open-label phase 2 study to evaluate TT-00973-MS tablets in combination with firmonertinib mesylate tablets in patients with locally advanced or metastatic non-small cell lung cancer.Based on the results of the study, the parties may collaborate on a phase 3 study.

HKG:2617
Asia

TransThera Sciences Seeks HK$156 Million via Share Offering

TransThera Sciences (Nanjing) (HKG:2617) said it was looking to raise HK$156.6 million via a share offering, according to a Tuesday filing with the Hong Kong bourse.The drugmaker is seeking investors for 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product tinengotinib.The shares represent 1.24% of the company's existing H shares and 0.95% of its total issued shares, and 1.23% and 0.94% as enlarged by the offering, respectively.TransThera recently said that tinengotinib was found to offer benefit to patients in a clinical trial conducted in China.Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.

HKG:2617
Asia

TransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial

TransThera Sciences (Nanjing) (HKG:2617) said its anti-tumor drug candidate, tinengotinib, was found to offer benefit to patients in a clinical trial conducted in China, according to a Sunday filing with the Hong Kong bourse.Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.Subjects who received tinengotinib as a monotherapy achieved an objective response rate of 16.7%, while those in the combination arm had an ORR of 22.6%, the firm said.

HKG:2617
Asia

TransThera Sciences Raises HK$282.2 Million from Share Placement

TransThera Sciences (Nanjing) (HKG:2617) completed the placing of nearly 5.1 million shares to at least six investors at a net issue price of HK$55.49 apiece to raise net proceeds HK$282.2 million, according to a Tuesday Hong Kong bourse filing.The shares represent 1.65% of the clinical-stage biopharmaceutical firm's issued Hong Kong-listed shares and 1.26% of its total issued share capital as enlarged by the placing.The firm will use proceeds for research and development, the manufacturing and commercialization of core product Tinengotinib in China, and working capital and general corporate purposes.

HKG:2617
Asia

TransThera Sciences Doses First Patient in Cholangiocarcinoma Drug Trial

TransThera Sciences (Nanjing) (HKG:2617) dosed the first patient in a confirmatory phase III clinical trial of Tinengotinib, according to a Friday Hong Kong bourse filing.The drug is being tested as a monotherapy for the treatment of patients with advanced cholangiocarcinoma, the clinical-stage biopharmaceutical firm said.

HKG:2617
Asia

TransThera Sciences to Raise HK$282 Million via Share Placement

TransThera Sciences (Nanjing) (HKG:2617) plans to raise about HK$282.2 million in net proceeds through a share placement, according to a Wednesday Hong Kong bourse filing.The clinical-stage biopharmaceutical firm agreed to place 5.1 million shares at HK$57.03 each to at least six independent investors.The placing price represents a discount of about 18% to the last closing price and about 19.2% to the five-day average price, the filing said.The placing shares represent about 1.3% of the company's existing issued share capital.Net proceeds will be used mainly for research and development and commercialization of its core product, Tinengotinib, as well as working capital.

HKG:2617

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2617 in your portfolio
WheelAI
WheelAI
Analyze HKG:2617 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2617